{"id":7313,"date":"2020-01-15T17:35:19","date_gmt":"2020-01-15T12:05:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7313"},"modified":"2022-02-11T12:32:26","modified_gmt":"2022-02-11T07:02:26","slug":"malignant-pleural-mesothelioma-upcoming-therapies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies","title":{"rendered":"Malignant Pleural Mesothelioma Upcoming Therapies"},"content":{"rendered":"

<\/p>\n\n\n

The Malignant Pleural Mesothelioma Market<\/a> includes several immunotherapy agents, in the pipeline including Keytruda<\/strong>, Opdivo<\/strong> and Yervoy<\/strong>, which have shown promising anticancer activity against mesothelioma in recent clinical trials. These drugs have been approved for other indications and now are being used in mono or combination therapy for mesothelioma. The most promising checkpoint inhibitors in mesothelioma research currently include Keytruda, Opdivo, Yervoy and Imfinzi (Durvalumab).<\/p>\n\n\n\n

Yervoy<\/strong> (ipilimumab for injection) is a recombinant, fully human monoclonal antibody that binds to and blocks human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Opdivo is a programmed death receptor-1 (PD-1) blocking antibody. Yervoy,<\/strong> in combination with Opvido<\/strong> is currently in the trial phase for the treatment of mesothelioma and is in clinical trials conducted by Bristol Myers Squibb.<\/p>\n\n\n\n

Amphera\u2019s lead product MesoPher<\/strong> is currently in phase II\/III for pleural mesothelioma<\/a>. MesoPher is comprised of autologous patient dendritic cells (DCs) loaded with PheraLys (Amphera’s allogeneic lysate of mesothelioma cell lines). <\/p>\n\n\n\n

Defactinib<\/strong> (VS-6063), developed by Verastem Inc., is currently in phase II for Malignant pleural mesothelioma treatment<\/a>.<\/a> Cells treated with VS\u20106063 alone or VS\u20106063 plus pemetrexed showed little or no tumour-initiating capacity. It is in Phase 1\/2 collaboration with Merck & Co. and Cancer Research UK to evaluate combination therapy with pembrolizumab for different types of cancer.\u00a0<\/p>\n\n\n\n

ONCOS-102<\/strong>, developed by Targovax, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated for Mesothelioma treatment<\/a>. In February 2019, Targovax reported interim data for the first six patients of the ongoing ONCOS-102 trial. These results suggested that patients might benefit from more injections of Targovax\u2019s oncolytic virus.<\/p>\n\n\n\n

Valproate, DHAC, belinostat, decitabine and vorinostat are epi-drugs that have been studied in clinical trials for mesothelioma.<\/p>\n\n\n\n

Along with the above-mentioned treatment approach, there are other few companies which have been focusing on the development of novel therapies for the treatment of Mesothelioma. Overall, a robust pipeline filled with novel therapies along with the need for effective curative therapies will lead to a boost to the market revenue generated during the forecast period [2017-2028].
<\/p>\n","protected":false},"excerpt":{"rendered":"

The Malignant Pleural Mesothelioma Market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy, which have shown promising anticancer activity against mesothelioma in recent clinical trials. These drugs have been approved for other indications and now are being used in mono or combination therapy for mesothelioma. The most promising checkpoint inhibitors in […]<\/p>\n","protected":false},"author":1,"featured_media":7314,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[345,4247,7692,7691,7693,17962,17961,431,609],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-7313","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-keytruda","tag-malignant-pleural-mesothelioma","tag-malignant-pleural-mesothelioma-epidemiology","tag-malignant-pleural-mesothelioma-market","tag-malignant-pleural-mesothelioma-pipeline","tag-malignant-pleural-mesothelioma-treatment-market","tag-malignant-pleural-mesothelioma-upcoming-therapies","tag-opdivo","tag-yervoy","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nMalignant Pleural Mesothelioma Treatment Market | MPM Pipeline Analysis<\/title>\n<meta name=\"description\" content=\"Malignant pleural mesothelioma treatment market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Malignant Pleural Mesothelioma Treatment Market | MPM Pipeline Analysis\" \/>\n<meta property=\"og:description\" content=\"Malignant pleural mesothelioma treatment market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-15T12:05:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-11T07:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/15173219\/malignant-Pleural.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Malignant Pleural Mesothelioma Treatment Market | MPM Pipeline Analysis","description":"Malignant pleural mesothelioma treatment market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies","og_locale":"en_US","og_type":"article","og_title":"Malignant Pleural Mesothelioma Treatment Market | MPM Pipeline Analysis","og_description":"Malignant pleural mesothelioma treatment market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy.","og_url":"https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-01-15T12:05:19+00:00","article_modified_time":"2022-02-11T07:02:26+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/15173219\/malignant-Pleural.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies","url":"https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies","name":"Malignant Pleural Mesothelioma Treatment Market | MPM Pipeline Analysis","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/15173219\/malignant-Pleural.jpg","datePublished":"2020-01-15T12:05:19+00:00","dateModified":"2022-02-11T07:02:26+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Malignant pleural mesothelioma treatment market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/malignant-pleural-mesothelioma-upcoming-therapies#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/15173219\/malignant-Pleural.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/15173219\/malignant-Pleural.jpg","width":772,"height":482,"caption":"Malignant Pleural Mesothelioma"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/15173219\/malignant-Pleural-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">malignant pleural mesothelioma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Malignant pleural mesothelioma epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Malignant pleural mesothelioma market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Malignant pleural mesothelioma pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Malignant Pleural Mesothelioma Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Malignant Pleural Mesothelioma Upcoming Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Opdivo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Yervoy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Keytruda<\/span>","<span class=\"advgb-post-tax-term\">malignant pleural mesothelioma<\/span>","<span class=\"advgb-post-tax-term\">Malignant pleural mesothelioma epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Malignant pleural mesothelioma market<\/span>","<span class=\"advgb-post-tax-term\">Malignant pleural mesothelioma pipeline<\/span>","<span class=\"advgb-post-tax-term\">Malignant Pleural Mesothelioma Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Malignant Pleural Mesothelioma Upcoming Therapies<\/span>","<span class=\"advgb-post-tax-term\">Opdivo<\/span>","<span class=\"advgb-post-tax-term\">Yervoy<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jan 15, 2020","modified":"Updated on Feb 11, 2022"},"absolute_dates_time":{"created":"Posted on Jan 15, 2020 5:35 pm","modified":"Updated on Feb 11, 2022 12:32 pm"},"featured_img_caption":"Malignant Pleural Mesothelioma","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7313"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7313\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7314"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7313"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7313"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}